Dr. Faoro is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2 Tower Pl
South San Francisco, CA 94080- Is this information wrong?
Summary
- Experienced board-certified medical oncologist and drug developer with more than 15 years of clinical research experience, spanning phase I-IV, with experience filing INDs and BLA/NDAs. Experience in US and Global oncology clinical studies. I have worked on small molecules, and biologics, from signal transduction inhibitors to antibody-drug conjugates and other large molecule constructs.
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 2005 - 2009
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2002 - 2005
Federal University of Parana Faculty of MedicineClass of 2001
Clinical Trials
- A Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer (BRIDGE) Start of enrollment: 2005 Sep 01
- A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies Start of enrollment: 2012 Oct 01
- A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors Start of enrollment: 2013 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- 8 citationsA Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg P...Jaume Capdevila, Arkadiy Klochikhin, Sophie Leboulleux, Pavel Isaev, Corin Badiu, Bruce Robinson, Brett G M Hughes, Bhumsuk Keam, Francis Parnis, Rossella Elisei, Pabl...> ;Thyroid. 2022 May 1
- 24 citationsA Phase 1a/b Open‑Label, Dose‑Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors.Niharika B. Mettu, Susanna Varkey Ulahannan, Johanna C. Bendell, Ignacio Garrido-Laguna, John H. Strickler, Kathleen N. Moore, Robert J. Stagg, Ann M. Kapoun, Leonardo...> ;Clinical Cancer Research. 2021 Nov 29
- 91 citationsCabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.Marcia S. Brose, Bruce G. Robinson, Steven I. Sherman, Jolanta Krajewska, Chia-Chi Lin, Fernanda Vaisman, Ana O. Hoff, Erika Hitre, Daniel W. Bowles, Jorge Hernando, L...> ;The Lancet. Oncology. 2021 Aug 1
- Join now to see all
Press Mentions
Quanta Therapeutics Appoints Leonardo Faoro, MD, as Chief Medical OfficerDecember 13th, 2022- Quanta Therapeutics Appoints Leonardo Faoro, MD, as Chief Medical OfficerDecember 13th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
